Cough News and Research

RSS

Study examines alternative immunization schedule occurrence rates in Washington State

Seventy-seven percent of Washington state pediatricians report that they are sometimes or frequently asked to provide alternative childhood vaccine schedules for their patients, according to a new study from Seattle Children's Research Institute. Researchers also found that 61 percent of Washington state pediatricians are comfortable using an alternative schedule when asked by a parent.

30 Nov 2011

Many kids missing vaccinations owing to parental refusal: Report

Figures reveal that more parents are opting out of school shots for their kids. In eight states now, more than one in 20 public school kindergarten children aren't getting all the vaccines required for attendance.

29 Nov 2011

Pediatricians frequently asked to provide alternative childhood vaccine schedules

29 Nov 2011

Pediatricians warn about hazards of button batteries

With the increasing production of electronic products in the consumer market, more button batteries are found in the home setting. From remote controls and watches to musical greeting cards and toys, these small, shiny objects are the perfect size for a curious child to swallow or even push into their nasal cavity or ear canal. It is important for parents to be aware of the dangers that button batteries pose to young children and the damage that these batteries can cause.

23 Nov 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

New 'triggered imaging' enables physicians to better target tumors during radiosurgery

A new type of "triggered imaging" technology enables University of Alabama at Birmingham physicians to better target tumors during radiosurgery and lessens the risk of injury to surrounding lung tissue.

22 Nov 2011

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.

21 Nov 2011

Valeant signs agreement to acquire iNova

Valeant Pharmaceuticals International, Inc. announced today that it has signed an agreement to acquire iNova, a private pharmaceutical group which sells and distributes a range of prescription and over-the-counter (OTC) products in Australia, New Zealand, Southeast Asia and South Africa from Archer Capital, Ironbridge and other minority management shareholders.

21 Nov 2011

Alcohol-based hand sanitizer helps reduce influenza A in children

A hand and respiratory hygiene program including frequent use of alcohol-based hand sanitizer helps reduce illness caused by influenza A and missed school days in elementary school children, reports a study in the November issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

15 Nov 2011

Wood stoves with chimneys linked to reduced childhood pneumonia

Cooking stoves with chimneys can lower exposure to indoor wood smoke and reduce the rate of severe pneumonia by 30 percent in children less than 18 months of age, according to a new air pollution study funded by the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health.

11 Nov 2011

New data from Novartis' ACZ885 Phase III study on SJIA

Novartis announced today new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885.

7 Nov 2011

Sunovion reports positive results from ciclesonide nasal aerosol Phase III study for perennial allergic rhinitis

Sunovion Pharmaceuticals Inc. today announced results from a large Phase III clinical study of ciclesonide nasal aerosol, a corticosteroid formulated with a hydrofluoroalkane (HFA) propellant, intended for the treatment of allergic rhinitis.

5 Nov 2011

Vitamin D levels not related to acute exacerbations of chronic obstructive pulmonary disease

Vitamin D levels are not related to acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in patients with severe COPD, according to a large prospective cohort study involving 973 North American patients. The findings were published online ahead of the print edition of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

4 Nov 2011

Final results from Vertex KALYDECO second of two Phase 3 studies on CF

Vertex Pharmaceuticals Incorporated today announced final results from the ENVISION study, the second of two pivotal Phase 3 studies of KALYDECO, a medicine in development that targets the defective protein that causes cystic fibrosis.

4 Nov 2011

Measles virus develops a strategy of diabolic elegance

Mayo Clinic researchers have discovered why measles, perhaps the most contagious viral disease in the world, spreads so quickly. The virus emerges in the trachea of its host, provoking a cough that fills the air with particles ready to infect the next host. The findings may also help in the fight against ovarian, breast and lung cancers.

3 Nov 2011

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.

2 Nov 2011

New Mayo Clinic social network connects global community of esophageal cancer patients

In 2008, physicians at Mayo Clinic Florida led by Herbert Wolfsen, M.D., were looking for new ways to keep in touch with the large group of esophageal cancer patients cared for by him and other gastroenterologists and surgeons. Telephone calls, faxes and email had worked to create a network of patients but many now wanted interactive and remote access capability to share their experiences and challenges with this serious disease.

1 Nov 2011

ProPhase Labs introduces new Cold-EEZE Oral Spray

ProPhase Labs, makers of Cold-EEZE, a leader in over-the-counter (OTC) homeopathic cold remedies, continues to pioneer the category as they launch their first-ever Cold-EEZE Oral Spray. The new Oral Spray is formulated with zinc gluconate, the same effective active ingredient found in the best-selling, clinically proven and #1 pharmacist recommended Cold-EEZE lozenges.